Your browser doesn't support javascript.
loading
IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells.
Lee, Jaewoong; Robinson, Mark E; Ma, Ning; Artadji, Dewan; Ahmed, Mohamed A; Xiao, Gang; Sadras, Teresa; Deb, Gauri; Winchester, Janet; Cosgun, Kadriye Nehir; Geng, Huimin; Chan, Lai N; Kume, Kohei; Miettinen, Teemu P; Zhang, Ye; Nix, Matthew A; Klemm, Lars; Chen, Chun Wei; Chen, Jianjun; Khairnar, Vishal; Wiita, Arun P; Thomas-Tikhonenko, Andrei; Farzan, Michael; Jung, Jae U; Weinstock, David M; Manalis, Scott R; Diamond, Michael S; Vaidehi, Nagarajan; Müschen, Markus.
Afiliação
  • Lee J; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Robinson ME; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Ma N; Department of Computational and Quantitative Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Artadji D; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Ahmed MA; Department of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Xiao G; Department of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Sadras T; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Deb G; Department of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Winchester J; Department of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Cosgun KN; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Geng H; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Chan LN; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Kume K; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Miettinen TP; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Zhang Y; Medical Research Council Laboratory for Molecular Cell Biology, University College London, London, UK.
  • Nix MA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Klemm L; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Chen CW; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Chen J; Department of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Khairnar V; Department of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Wiita AP; Department of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Thomas-Tikhonenko A; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Farzan M; Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Jung JU; Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA.
  • Weinstock DM; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Manalis SR; Dana Farber Cancer Institute, Boston, MA, USA.
  • Diamond MS; Harvard Medical School, Boston, MA, USA.
  • Vaidehi N; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Müschen M; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Nature ; 588(7838): 491-497, 2020 12.
Article em En | MEDLINE | ID: mdl-33149299
ABSTRACT
Interferon-induced transmembrane protein 3 (IFITM3) has previously been identified as an endosomal protein that blocks viral infection1-3. Here we studied clinical cohorts of patients with B cell leukaemia and lymphoma, and identified IFITM3 as a strong predictor of poor outcome. In normal resting B cells, IFITM3 was minimally expressed and mainly localized in endosomes. However, engagement of the B cell receptor (BCR) induced both expression of IFITM3 and phosphorylation of this protein at Tyr20, which resulted in the accumulation of IFITM3 at the cell surface. In B cell leukaemia, oncogenic kinases phosphorylate IFITM3 at Tyr20, which causes constitutive localization of this protein at the plasma membrane. In a mouse model, Ifitm3-/- naive B cells developed in normal numbers; however, the formation of germinal centres and the production of antigen-specific antibodies were compromised. Oncogenes that induce the development of leukaemia and lymphoma did not transform Ifitm3-/- B cells. Conversely, the phosphomimetic IFITM3(Y20E) mutant induced oncogenic PI3K signalling and initiated the transformation of premalignant B cells. Mechanistic experiments revealed that IFITM3 functions as a PIP3 scaffold and central amplifier of PI3K signalling. The amplification of PI3K signals depends on IFITM3 using two lysine residues (Lys83 and Lys104) in its conserved intracellular loop as a scaffold for the accumulation of PIP3. In Ifitm3-/- B cells, lipid rafts were depleted of PIP3, which resulted in the defective expression of over 60 lipid-raft-associated surface receptors, and impaired BCR signalling and cellular adhesion. We conclude that the phosphorylation of IFITM3 that occurs after B cells encounter antigen induces a dynamic switch from antiviral effector functions in endosomes to a PI3K amplification loop at the cell surface. IFITM3-dependent amplification of PI3K signalling, which in part acts downstream of the BCR, is critical for the rapid expansion of B cells with high affinity to antigen. In addition, multiple oncogenes depend on IFITM3 to assemble PIP3-dependent signalling complexes and amplify PI3K signalling for malignant transformation.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos B / Transdução de Sinais / Proteínas de Ligação a RNA / Fosfatos de Fosfatidilinositol / Fosfatidilinositol 3-Quinases / Proteínas de Membrana Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Nature Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos B / Transdução de Sinais / Proteínas de Ligação a RNA / Fosfatos de Fosfatidilinositol / Fosfatidilinositol 3-Quinases / Proteínas de Membrana Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Nature Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos